MANSFIELD, Mass., Dec. 1, 2011 /PRNewswire/ -- PrimeraDx today announced that David Heffelfinger has been appointed as Vice President of Engineering and Systems Development.
"It is an exciting time to join PrimeraDx. The ICEPlex® System offers a glimpse into the future of molecular diagnostics, providing capabilities that are essential and timely," Commented Mr. Heffelfinger.
"David brings to PrimeraDx extensive experience in the medical device industry and is a great addition to the executive team. His knowledge and background in engineering and systems development, as well as his quality systems experience and six sigma training, are well aligned with the Company's strategy to provide next generation molecular diagnostics to the clinical laboratory market," said President and CEO Matthew McManus.
Mr. David Heffelfinger has held many Executive-level engineering positions within life science and medical device companies including Beckman Coulter, BD Biosciences, and Bio-Rad Laboratories as well as several startups and venture capital backed companies including Biometric Imaging, Alpha Innotech Corp, and Luminys Systems. Dave was also a founder of his own company, Hyperspectra LLC. He began his professional career at General Motors Research Laboratories in Warren, Michigan as an Applied Physicist. He received his B.S. and M.S. in Physics from Wayne State University and an Executive MBA from Saint Mary's College in Moraga, California. He holds 27 US and international patents in the fields of imaging, optics, bio-systems, and instrumentation.
PrimeraDx is a molecular diagnostics company that has developed, and is commercializing, a novel, game-changing clinical platform which combines PCR with capillary electrophoresis. The result of combining these two well-known technologies into a bench-top instrument is the ability to deliver highly multiplexed and quantitative, answers to the clinic. The company is pursuing a two-pronged strategy to sell the system in an Open Platform Mode to clinical labs and to collaborate with pharmaceutical companies to develop high-value companion and enabling diagnostic products. Users can easily design very complex multi-modal assays that test for disparate target types, like SNPs, expression biomarkers, microRNAs and fusion genes. PrimeraDx's technology represents the next generation of quantitative PCR. The Company is backed by a strong group of experienced venture-capital investors, including Abingworth, InterWest Partners, CHL Medical Partners, and Malaysia Technology Development Corporation. The Company's website is: www.primeradx.com or www.multiplexpcr.com.
CONTACT: Andrew Bond, +1-508-618-2752, firstname.lastname@example.org